- Report
- March 2025
- 179 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- August 2022
- 119 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- December 2020
- 120 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2022
Global
From €751EUR$790USD£631GBP
- Report
- November 2024
- 93 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- August 2022
- 106 Pages
Global
From €1901EUR$2,000USD£1,597GBP
The Rabies Drug market is a subset of the biotechnology industry that focuses on the development and production of drugs and treatments for rabies. Rabies is a viral disease that affects the central nervous system and is transmitted through the saliva of infected animals. The market is driven by the need to develop effective treatments and vaccines to prevent the spread of the disease.
The market is composed of a variety of companies, including pharmaceutical companies, biotechnology companies, and research institutions. These companies are involved in the development of new treatments and vaccines, as well as the production and distribution of existing treatments and vaccines. Companies in the Rabies Drug market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. Show Less Read more